Suggested remit - To appraise the clinical and cost effectiveness of guselkumab within its marketing authorisation for treating active psoriatic arthritis.
Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
 
Status Schedule affected by COVID-19
Process STA 2018
ID number 1658

Provisional Schedule

Expected publication 30 June 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Janssen-Cilag (guselkumab)
Others Department of Health and Social Care
Patient carer groups Psoriasis and Psoriatic Arthritis Alliance
  Psoriasis Association
Professional groups British Society for Rheumatology
  Royal College of Physicians

Commentators

Comparator companies Abbvie (adalimumab)
  Amgen (adalimumab)
  Biogen (adalimumab, etanercept, infliximab)
  Bristol-Myers Squibb (abatacept)
  Eli Lilly and Company (ixekuzimab)
  Janssen-Cilag (ustekinumab)
  Novartis Pharmaceuticals (ciclosporin, secukinumab)
  Pfizer (infliximab, etanercept, methotrexate, sulfasalazine, tofacitinib)
  UCB Pharma (certolizumab pegol)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
14 April 2021 Committee meeting
04 March 2021 - 25 March 2021 Appraisal consultation
11 February 2021 Committee meeting
09 June 2020 Invitation to participate
13 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
08 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
20 November 2019 - 18 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance